Literature DB >> 7055977

Defective ornithine metabolism in cultured skin fibroblasts from patients with the syndrome of hyperornithinemia, hyperammonemia and homocitrullinuria.

V E Shih, R Mandell, A Herzfeld.   

Abstract

The syndrome of hyperornithinemia, hyperammonemia, and homocitrullinuria (HHH) is a metabolic disorder resulting in protein intolerance and mental retardation. The primary metabolic defect has yet to be determined. We studied some aspects of ornithine metabolism in cultured skin fibroblasts from two patients from two patients with the HHH syndrome. The fibroblasts failed to incorporate 14C-label from ornithine into protein, a defect also observed in fibroblasts from patients with gyrate atrophy of the choroid and retina and a deficiency of ornithine aminotransferase activity. The defect can be corrected in heterokaryons formed between these two types of fibroblasts. These findings indicate that fibroblasts are suitable for further studying the underlying metabolic defect in HHH syndrome. The combination of the ornithine incorporation assay and genetic complementation analysis provide a confirmatory test for the diagnosis of this syndrome.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7055977     DOI: 10.1016/0009-8981(82)90002-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Ornithine aminotransferase deficiency: diagnostic difficulties in neonatal presentation.

Authors:  M A Cleary; L Dorland; T J de Koning; B T Poll-The; M Duran; R Mandell; V E Shih; R Berger; S E Olpin; G T N Besley
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  A new patient with hyperornithinaemia, hyperammonaemia and homocitrullinuria treated early with low protein diet.

Authors:  L R Gjessing; H A Lunde; T Undrum; H Broch; A Alme; S O Lie
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  Abnormality of citrulline synthesis in liver mitochondria from patients with hyperornithinaemia, hyperammonaemia and homocitrullinuria.

Authors:  I Inoue; M Koura; T Saheki; K Kayanuma; M Uono; M Nakajima; K Takeshita; R Koike; T Yuasa; T Miyatake
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

4.  The mechanism of hyperammonaemia and hyperornithinaemia in the syndrome of hyperornithinaemia, hyperammonaemia with homocitrullinuria.

Authors:  K Oyanagi; A Tsuchiyama; Y Itakura; H Sogawa; K Wagatsuma; T Nakao; S Sakamoto; A Yachi
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

5.  Studies on the pathway from ornithine to proline in cultured skin fibroblasts with reference to the defect in hyperornithinaemia with hyperammonaemia and homocitrullinuria.

Authors:  R G Gray; S E Hill; R J Pollitt
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

6.  Comparison of ornithine metabolism in hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome, lysinuric protein intolerance and gyrate atrophy fibroblasts.

Authors:  J Botschner; D W Smith; O Simell; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

7.  The pH of mitochondria of fibroblasts from a hyperornithinaemia, hyperammonaemia, homocitrullinuria-syndrome patient.

Authors:  K Metoki; F A Hommes
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

Review 8.  The biochemical basis of mitochondrial diseases.

Authors:  H R Scholte
Journal:  J Bioenerg Biomembr       Date:  1988-04       Impact factor: 2.945

9.  Ultrastructural changes in fibroblast mitochondria of a patient with HHH-syndrome.

Authors:  K Metoki; F A Hommes; P Dyken; C Kelloes; J Trefz
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

10.  Molybdenum cofactor biosynthesis in humans. Identification of two complementation groups of cofactor-deficient patients and preliminary characterization of a diffusible molybdopterin precursor.

Authors:  J L Johnson; M M Wuebbens; R Mandell; V E Shih
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.